RE:RE:RE:RE:RE:RE:RE:RE:POCI agree that in phase Ia it was hard to get biopsies and so on, but I gave the example of Immunomedics that had Trop-2 expression results for all the patients of their phase I, even though they did not enroll patients based on the criteria of Trop-2 expression, but at least, once the trial was over, they knew that a bit over 75% of the patients enrolled were overexpressinfg Trop-2.
So I understand they cannot have an imaging tool before 2 or 3 years, if they would start to work on it right now. I also understand that biopsies on very advanced patients are hard to get, but in phase Ib they need to find a way to correlate efficacy with sortilin expression. To have a bulletproof scientific proof of concept, you need that.
Also, I have a hard time thinking that they had no data at all on sortilin expression from phase Ia. I also have a hard time believing they published that data without confirmation that these three patients had some level of sortilin overexpression on their tumors. I still don't understand why they did not said a word about that. It's an intergral part of their platform. It's called SORT1+ for sortilin, but not a word on sortilin with the first results on human patients. Results on a targeted drug without a word about the target. It's beyond strange.
Wino115 wrote: I re-listened to Paul at the CS Healthcare event on THTX website. He responded to the analyst asking a question about sortilin expression on tumors. He said .. of course we can't know the sortilin expression prior to treatment in this phase of the trial, but we can get a reading afterwards. This is me paraphrasing, but it could be a quote. So they may have tried to do biopsy after on some patients to understand that better. But as we've said, it's probably just the staging to show mid-high-very high. Further, the patient would have to survive and be in shape for a biopsy. It may be more likely they get better data in 1b and 2. Just seems very difficult in this patient cohort.